Data from many controlled clinical trials and real-life experiences with Palbociclib—a highly selective cyclin-dependent kinase 4/6 inhibitor (CDK4/6), modulating the COX2-pathway—demonstrated a significant improvement in the prognosis of metastatic BC [26]. Here, CDK4 is linked to breast cancer.